Live Feeds
● LIVE Updated 2h ago · 14 sources tracked

Clues to Why a Breakthrough Pancreatic Cancer Drug Eventually Stops Working

Researchers are investigating why patients inevitably develop resistance to the breakthrough pancreatic cancer drug daraxonrasib. Developed by the Dana-Farber Cancer Institute and manufactured by Revolution Medicines, the medication works by blocking specific gene mutations that drive abnormal cell growth. The treatment showed so much early promise that the FDA approved it more than six months ahead of schedule. However, patients eventually stop responding to the therapy. A preliminary study recently examined biopsies from 66 patients in an early-stage trial to uncover how tumors manage to evade the drug.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (14)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Daraxonrasib was developed by the Dana-Farber Cancer Institute.
  • ✓ The FDA approved daraxonrasib more than six months ahead of schedule.
  • ✓ Revolution Medicines produces daraxonrasib.
  • ✓ A preliminary study analyzed biopsies from 66 patients enrolled in an early-stage trial.
🛡️ Source Corroboration: 14 independent reporting domains (90% confidence) ⏱ Read time: ~2 min

What changed

A preliminary study analyzed biopsies from 66 clinical trial patients to identify early clues regarding how pancreatic tumors evade daraxonrasib.

Live updates

  1. Clues Emerge on Why Pancreatic Cancer Drug Daraxonrasib Fails

    Researchers are investigating why patients inevitably develop resistance to the breakthrough pancreatic cancer drug daraxonrasib. Developed by the Dana-Farber Cancer Institute and manufactured by Revolution Medicines, the medication works by blocking specific gene mutations that drive abnormal cell growth. The treatment showed so much early promise that the FDA approved it more than six months ahead of schedule. However, patients eventually stop responding to the therapy. A preliminary study recently examined biopsies from 66 patients in an early-stage trial to uncover how tumors manage to evade the drug.

    Why it matters

    Pancreatic cancer has historically presented immense treatment challenges, making the arrival of a drug capable of targeting core genetic drivers a significant milestone. The FDA expedited approval of daraxonrasib due to its promising initial performance against advanced disease. Despite this early success, understanding resistance mechanisms is vital to prolonging patient responses and improving long-term survival outcomes.

    What is confirmed

    • Daraxonrasib was developed by the Dana-Farber Cancer Institute.
    • The FDA approved daraxonrasib more than six months ahead of schedule.
    • Revolution Medicines produces daraxonrasib.
    • A preliminary study analyzed biopsies from 66 patients enrolled in an early-stage trial.

    Still unconfirmed

    • Former Senator Ben Sasse is among the patients who developed resistance to daraxonrasib.

    What to watch next

    • Further findings from the ongoing analysis of patient biopsies from the early-stage trial
    • Clinical developments targeting how pancreatic tumors evade daraxonrasib treatment
    Sources used for this update (13)
    1. www.wbur.org — How an Mass. researcher's lab made a breakthrough in pancreatic cancer treatment
    2. The New York Times — Clues to Why a Breakthrough Pancreatic Cancer Drug Eventually Stops Working
    3. WBUR — How a Mass. researcher's lab made a breakthrough in pancreatic cancer treatment
    4. Gizmodo — This Pill Will Change Cancer Treatment Forever
    5. Arizona PBS — Arizona’s connection to a new pancreatic cancer treatment
    6. GlobeNewswire — AIM ImmunoTech Discusses Ampligen®’s Potential to
    7. medscape.com — How Scientists Finally Cracked RAS in Pancreatic Cancer
    8. www.adamkinzinger.com — BREAKING: Trump Approval Hits Record Low, Elon Musk Gets Job At Pentagon, Trump Surrenders To AI Giants, ....
    9. flipboard.com — This Pill Will Change Cancer Treatment Forever
    10. article.wn.com — Clues to Why a Breakthrough Pancreatic Cancer Drug Eventually ...
    11. www.zetik.com — Researchers Trace Daraxonrasib Resistance in 66 Pancreatic ...
    12. singlinkbot.com — Why Breakthrough Pancreatic Cancer Drug Eventually Fails ...
    confidence 90%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community